Paul Romness, Chair, CEO, and President of OS Therapies, joins our hosts to discuss the company’s investigational immunotherapy for osteosarcoma and its approach to targeting cancer through the immune system. He also highlights clinical findings and the company’s path toward potential regulatory approval.
February 7, 2023
